Effects of Calamansi on Blood Glucose and Insulin Levels
2026年5月13日 更新者:Piyapong Prasertsri、Burapha University
The Effects of Calamansi (Citrus x Macrocarpa Bunge) Supplementation on Blood Glucose and Insulin Levels in Healthy Volunteers
Fifty-four healthy sedentary male and female participants aged 18-30 years will be recruited for this study.
Participants will be randomly assigned to one of two groups: a control group receiving placebo MMC capsules (n = 27) or a calamansi capsule supplementation group (n = 27).
All participants will undergo health screening procedures, including medical history assessment, mental health questionnaire evaluation, and measurements of vital signs, height, body weight, and body composition.
Venous blood samples will subsequently be collected to determine blood glucose, insulin, creatinine, alanine aminotransferase (ALT), and malondialdehyde (MDA) levels.
These assessments will be performed at three time points: 1) before capsule supplementation (baseline), 2) following a single dose of capsule supplementation, and 3) after 12 weeks of supplementation.
研究概览
地位
招聘中
研究类型
介入性
注册 (估计的)
54
阶段
- 不适用
联系人和位置
本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。
学习联系方式
- 姓名:Piyapong Prasertsri, Ph.D.
- 电话号码:6638103166
- 邮箱:piyapong@buu.ac.th
研究联系人备份
- 姓名:Kulwara Poolpol, Ph.D.
- 电话号码:6638103147
- 邮箱:kulwara@go.buu.ac.th
学习地点
-
-
Burapha University
-
Mueang、Burapha University、泰国、20131
- 招聘中
- Piyapong Prasertsri
-
接触:
- Piyapong Prasertsri, Ph.D.
- 电话号码:6638103166
- 邮箱:piyapong@buu.ac.th
-
接触:
- Kulwara Poolpol, Ph.D.
- 电话号码:6638103147
- 邮箱:kulwara@go.buu.ac.th
-
-
参与标准
研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。
资格标准
适合学习的年龄
- 成人
接受健康志愿者
是的
描述
Inclusion Criteria:
- Healthy individuals who have not been diagnosed with diabetes or prediabetes, with a fasting blood glucose level (after 8 hours of fasting) of less than 100 mg/dL.
- Aged between 18-30 years, both male and female
- Body Mass Index (BMI) between 18.5 and 22.9 kg/m²
- No diseases affecting blood sugar levels, such as liver or pancreatic diseases
Exclusion Criteria:
- Pregnant or breastfeeding women
- Regular smokers
- Regular alcohol consumers
- Individuals with a history of allergies to citrus fruits or citrus-derived ingredients
- Individuals taking medications that affect glucose metabolism and fat distribution in the body, including steroids, protease inhibitors, and psychiatric medications. These refer to drugs that act on the central nervous system and may affect blood sugar levels or energy metabolism, such as antidepressants, antipsychotics, and mood stabilizers.
学习计划
本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。
研究是如何设计的?
设计细节
- 主要用途:预防
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:三倍
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
安慰剂比较:MMC powder capsule
Participants will be randomly assigned to an intervention arm.
During the short-term phase, participants in the control group will receive microcrystalline cellulose (MMC) capsules and will be instructed to consume 1,500 mg/day (three capsules).
During the long-term phase, participants will continue consuming MMC at a dose of 1,500 mg/day (three capsules), taken within 15-30 min after breakfast.
All supplementation will be administered at the participants' residences.
|
Each capsule contains MMC powder for 500 mg
|
|
实验性的:Calamansi powder capsule
Participants will be randomly assigned to an intervention arm.
During the short-term phase, participants in the calamansi group will receive calamansi powder capsules and will be instructed to consume 1,500 mg/day (three capsules).
During the long-term phase, participants will continue consuming calamansi powder capsules at a dose of 1,500 mg/day (three capsules), taken within 15-30 min after breakfast.
All supplementation will be administered at the participants' residences.
|
Each capsule contains calamansi powder for 500 mg
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Concentrations of blood glucose
大体时间:At 0 minute before consumption, at 30, 60, 90, 120 minutes after consumption, and at days 91 after consumption
|
Concentrations of blood glucose were measured before and after MMC capsules or calamansi capsule consumption at 500 mg in mg/dL unit
|
At 0 minute before consumption, at 30, 60, 90, 120 minutes after consumption, and at days 91 after consumption
|
|
Concentrations of blood insulin
大体时间:At 0 minute before consumption, at 120 minute after consumption, and at days 91 after consumption
|
Concentrations of blood insulin were measured before and after MMC capsules or calamansi capsule consumption at 500 mg in uU/mL (microunit/milliliter) unit
|
At 0 minute before consumption, at 120 minute after consumption, and at days 91 after consumption
|
|
Concentrations of blood malondialdehyde
大体时间:At 0 minute before consumption, at 120 minute after consumption, and at days 91 after consumption
|
Concentrations of blood malondialdehyde were measured before and after MMC capsules or calamansi capsule consumption at 500 mg in uM (micromolar) unit
|
At 0 minute before consumption, at 120 minute after consumption, and at days 91 after consumption
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Levels of heart rate variability
大体时间:At 0-10 minutes before consumption, at 110-120 minutes after consumption, and at days 91 after consumption for 10 minutes
|
Heart rate variability were measured before and after MMC capsules or calamansi capsule consumption at 500 mg in ms (milliseconds) and ms2 (millisecond squared) unit
|
At 0-10 minutes before consumption, at 110-120 minutes after consumption, and at days 91 after consumption for 10 minutes
|
合作者和调查者
在这里您可以找到参与这项研究的人员和组织。
调查人员
- 首席研究员:Piyapong Prasertsri, Ph.D.、Faculty of Allied Health Sciences, Burapha University
研究记录日期
这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。
研究主要日期
学习开始 (实际的)
2026年5月1日
初级完成 (估计的)
2026年12月31日
研究完成 (估计的)
2027年1月31日
研究注册日期
首次提交
2026年5月8日
首先提交符合 QC 标准的
2026年5月8日
首次发布 (实际的)
2026年5月14日
研究记录更新
最后更新发布 (实际的)
2026年5月15日
上次提交的符合 QC 标准的更新
2026年5月13日
最后验证
2026年5月1日
更多信息
与本研究相关的术语
其他研究编号
- IRB1-033/2569
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
不
IPD 计划说明
There is no plan to make individual participant data available to other researchers.
药物和器械信息、研究文件
研究美国 FDA 监管的药品
不
研究美国 FDA 监管的设备产品
不
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.